Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Gets A New Lawyer: Rebecca Wood Named Chief Counsel

Executive Summary

Former Sidley Austin partner brings a wealth of experience in drug product liability litigation and federal preemption. She replaces agency veteran Elizabeth Dickinson, who will stay on as senior deputy to the chief counsel.

You may also be interested in...



From White House To White Oak: US FDA Taps Stacy Cline Amin For Chief Counsel Post

The agency’s new top lawyer brings deep knowledge of FDA regulatory and legislative matters from her time on Capitol Hill and strong ties to the White House, where she has worked as special assistant and senior associate counsel to President Trump since early 2017.

From White House To White Oak: US FDA Taps Stacy Cline Amin For Chief Counsel Post

Agency’s new top lawyer brings deep knowledge of drug regulatory and legislative matters from her time on Capitol Hill and strong ties to the White House, where she has worked as special assistant and senior associate counsel to President Trump since early 2017.

US FDA Chief Counsel Rebecca Wood Steps Down

FDA will soon announce a permanent successor to Wood, who is leaving in July after about a year in the post, FDA Commissioner Gottlieb says. In the interim, Lowell Schiller, senior counsel to the commissioner and a former Senate HELP Committee staffer, will lead the chief counsel's office on an acting basis.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS121135

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel